TWI728173B - 病毒疫苗 - Google Patents

病毒疫苗 Download PDF

Info

Publication number
TWI728173B
TWI728173B TW106128111A TW106128111A TWI728173B TW I728173 B TWI728173 B TW I728173B TW 106128111 A TW106128111 A TW 106128111A TW 106128111 A TW106128111 A TW 106128111A TW I728173 B TWI728173 B TW I728173B
Authority
TW
Taiwan
Prior art keywords
virus
gene
adjuvant
composition
patent application
Prior art date
Application number
TW106128111A
Other languages
English (en)
Chinese (zh)
Other versions
TW201809273A (zh
Inventor
保羅 麥可 豪利
Original Assignee
澳大利亞商賽門堤斯有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016903295A external-priority patent/AU2016903295A0/en
Application filed by 澳大利亞商賽門堤斯有限公司 filed Critical 澳大利亞商賽門堤斯有限公司
Publication of TW201809273A publication Critical patent/TW201809273A/zh
Application granted granted Critical
Publication of TWI728173B publication Critical patent/TWI728173B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW106128111A 2016-08-19 2017-08-18 病毒疫苗 TWI728173B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
??2016903295 2016-08-19
AU2016903295A AU2016903295A0 (en) 2016-08-19 Viral Vaccines
AU2016903295 2016-08-19

Publications (2)

Publication Number Publication Date
TW201809273A TW201809273A (zh) 2018-03-16
TWI728173B true TWI728173B (zh) 2021-05-21

Family

ID=61195904

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106128111A TWI728173B (zh) 2016-08-19 2017-08-18 病毒疫苗

Country Status (18)

Country Link
US (2) US10905759B2 (enExample)
EP (2) EP4331676A3 (enExample)
JP (1) JP2019528271A (enExample)
KR (1) KR20190050787A (enExample)
CN (1) CN109862909A (enExample)
AR (1) AR110624A1 (enExample)
AU (1) AU2017313450B2 (enExample)
CA (2) CA3265584A1 (enExample)
CL (1) CL2019000405A1 (enExample)
IL (1) IL264893B (enExample)
MA (1) MA45994A (enExample)
MX (1) MX2019001919A (enExample)
MY (1) MY200887A (enExample)
NZ (1) NZ750578A (enExample)
SG (1) SG11201900814QA (enExample)
TW (1) TWI728173B (enExample)
WO (1) WO2018032057A1 (enExample)
ZA (1) ZA201900641B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020086423A1 (en) * 2018-10-22 2020-04-30 Icell Kealex Therapeutics Mutant vaccinia viruses and use thereof
US20210299245A1 (en) * 2020-03-31 2021-09-30 Sementis Limited Attenuated poxvirus vector based vaccine for protection against covid-19
CN112362877B (zh) * 2020-10-27 2024-04-12 江苏先声医学诊断有限公司 一种mbp重组蛋白以及其应用
KR102864666B1 (ko) * 2025-04-21 2025-09-29 대한민국 치쿤구니아 바이러스 외피 재조합 dna를 포함하는 백신 조성물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1418951A (zh) * 2001-05-23 2003-05-21 广州绿健生物技术有限公司 生产rna病毒和基于rna病毒的载体颗粒的组合物及方法
CN1754002A (zh) * 2002-08-12 2006-03-29 大卫·科恩 涉及痘病毒和癌的方法及组合物
US7767209B2 (en) * 2003-09-29 2010-08-03 Gsf-Forschungszentrum Fuer Umwelt Und Gesundheit Gmbh Modified vaccinia virus Ankara (MVA) mutant and use thereof
CN103200962A (zh) * 2010-09-23 2013-07-10 巴克斯特国际公司 重组病毒载体及用于诱导对黄热病毒的免疫反应的方法
CN105163756A (zh) * 2013-03-15 2015-12-16 赛门蒂斯有限公司 免疫调节
WO2016086980A1 (en) * 2014-12-02 2016-06-09 Consejo Superior De Investigaciones Cientificas Vaccine composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0758397B1 (en) * 1994-04-29 2005-06-22 Baxter Healthcare S.A. Recombinant poxviruses with foreign polynucleotides in essential regions
EP2253709B1 (en) * 2002-05-16 2018-04-11 Bavarian Nordic A/S Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
KR20040015624A (ko) 2002-08-13 2004-02-19 대한뉴팜(주) 플로르페니콜을 활성성분으로 함유하는 경구투여용약제학적 조성물
CN1723285B (zh) * 2003-02-18 2013-01-02 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 重组的mva及其产生方法
EP1683870A1 (en) * 2005-01-24 2006-07-26 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Vaccines based on the use of MVA
GB201006405D0 (en) * 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
US10544397B2 (en) * 2013-11-01 2020-01-28 Sementis Limited Viral vector manufacture
WO2017136419A1 (en) * 2016-02-03 2017-08-10 Geovax Inc. Compositions and methods for generating an immune response to a flavivirus

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1418951A (zh) * 2001-05-23 2003-05-21 广州绿健生物技术有限公司 生产rna病毒和基于rna病毒的载体颗粒的组合物及方法
CN1754002A (zh) * 2002-08-12 2006-03-29 大卫·科恩 涉及痘病毒和癌的方法及组合物
US7767209B2 (en) * 2003-09-29 2010-08-03 Gsf-Forschungszentrum Fuer Umwelt Und Gesundheit Gmbh Modified vaccinia virus Ankara (MVA) mutant and use thereof
CN103200962A (zh) * 2010-09-23 2013-07-10 巴克斯特国际公司 重组病毒载体及用于诱导对黄热病毒的免疫反应的方法
CN105163756A (zh) * 2013-03-15 2015-12-16 赛门蒂斯有限公司 免疫调节
WO2016086980A1 (en) * 2014-12-02 2016-06-09 Consejo Superior De Investigaciones Cientificas Vaccine composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Larocca RA et al., "Vaccine protection against Zika virus from Brazil", Nature 536, 474-478 (https://www.nature.com/articles/nature18952), 2016/06/28 *

Also Published As

Publication number Publication date
RU2019107582A (ru) 2020-09-21
IL264893A (enExample) 2019-04-30
SG11201900814QA (en) 2019-03-28
EP4331676A3 (en) 2024-05-15
TW201809273A (zh) 2018-03-16
CL2019000405A1 (es) 2019-06-14
US20200009245A1 (en) 2020-01-09
US10905759B2 (en) 2021-02-02
JP2019528271A (ja) 2019-10-10
MX2019001919A (es) 2019-09-04
AU2017313450A1 (en) 2019-02-28
EP4331676A2 (en) 2024-03-06
EP3500280A1 (en) 2019-06-26
AR110624A1 (es) 2019-04-17
US20210113684A1 (en) 2021-04-22
AU2017313450B2 (en) 2024-02-15
CN109862909A (zh) 2019-06-07
RU2019107582A3 (enExample) 2021-03-31
CA3034282A1 (en) 2018-02-22
IL264893B (en) 2022-08-01
NZ750578A (en) 2023-05-26
WO2018032057A1 (en) 2018-02-22
EP3500280A4 (en) 2020-05-13
KR20190050787A (ko) 2019-05-13
MA45994A (fr) 2021-03-17
MY200887A (en) 2024-01-22
CA3265584A1 (en) 2025-03-14
ZA201900641B (en) 2025-10-29
BR112019003181A2 (pt) 2019-07-16

Similar Documents

Publication Publication Date Title
JP3826055B2 (ja) 組換えアビポックスウイルスによる免疫方法
CN100540051C (zh) 用于接种新生儿的改良的安卡拉痘苗病毒
US20230381297A1 (en) Attenuated poxvirus vector based vaccine for protection against covid-19
CN104988124B (zh) 基因ⅶ型新城疫病毒标记疫苗株及其应用
US20210113684A1 (en) Vector-based attenuated poxvirus vaccines
JP2002514885A (ja) ポックスウイルス−イヌジステンパーウイルス（ｃｄｖ）組み換え体類および組成物類および前記組み換え体類を用いる方法
JP2003503039A (ja) 弱毒化したワクチンの操作のための方法および組成物
US20250099568A1 (en) Chimeric Flavivirus Lyssavirus Vaccines
WO2022071513A1 (ja) ＳＡＲＳ－ＣｏＶ－２に対する改良型ＤＮＡワクチン
KR20230022206A (ko) 코로나바이러스 질환에 대응하는 재조합적 변형된 우두증 바이러스 앙카라 (mva) 백신
JP2007105040A (ja) 組換体ポックスウイルス−ネコ感染性腹膜炎ウイルス、その組成物およびそれらの製造および使用方法
JP7387623B2 (ja) 標的タンパク質を安定して発現できる組換えウイルス
CN106255758A (zh) 病毒载体制造
US20130177582A1 (en) Parapoxvirus expressing the vp60 major capsid protein of the rabbit haemorrhagic disease virus
RU2778312C2 (ru) Вирусные вакцины
BR112019003181B1 (pt) Composição para aumentar uma resposta imune em animal, método para induzir uma resposta imune protetora em um sujeito, e, uso da composição na preparação de um medicamento
CN110144002A (zh) 甲型流感病毒哺乳动物细胞适应株及其制备和应用

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees